Skip to main content

Table 2 Clinical outcomes at 30 days and 3 years*

From: Admission hyperglycemia and adverse outcomes in diabetic and non-diabetic patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention

Variable Description Participants without diabetes mellitus Participants with diabetes mellitus
Group1 Group 2 Group3 Group 4
APG < 44 mg/dL
n = 470
APG ≥144 mg/dL
n = 184
APG < 180 mg/dL
n = 133
APG ≥180 mg/dL
n = 103
30-day outcomes (%)
 Death, all-cause 2 (0.4)*§ + 7 (3.8)*§ + 3 (2.3)# § + 9 (8.7)# § +
 Cardiac 2 (0.4)*§ + 6 (3.3)*§ + 2 (1.5)# § + 8 (7.8)# § +
 Non-cardiac 0 (0.0) 1 (0.5) 1 (0.8) 1 (1.0)
 Reinfarction 0 (0.0) 1 (0.5) 1 (0.8) 1 (1.0)
 HF required hospital admission 3 (0.6)*§ + 5 (2.7)*§ + 2 (1.5)# § + 6 (5.8)# § +
 Ischemic TVR 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Stroke 0 (0.0)*§ 2 (1.1)*§ 1 (0.8)§ 1 (1.0)§
3-year outcomes (%)
 Death, all-cause 17 (3.6)*§ + 20 (10.9)*§+ 13 (9.8)# § + 20 (19.4)# § +
 Cardiac 14 (3.0)*§ + 17 (9.2)*§ + 12 (9.0)# § + 19 (18.4)# § +
 Non-cardiac 3 (0.6) 3 (1.6) 1 (0.8) 1 (1.0)
 Reinfarction 5 (1.1)*§ + 8 (4.3)*§ + 5 (3.8)§ + 9 (8.7)§ +
 HF required hospital admission 16 (3.4)*§ + 22 (12.0)*§ + 15 (11.3)§ + 18 (17.5)§ +
 Ischemic TVR 3 (0.6) 2 (1.1) 2 (1.5) 2 (1.9)
Stroke 4 (0.9)§ + 5 (2.7)§ + 2 (1.5)§ + 5 (4.9)§ +
  1. APG admission plasma glucose, HF heart failure, TVR target lesion revascularization
  2. *P < 0.05, Group 1 vs. Group 2
  3. # P < 0.05, Group 3 vs. Group 4
  4. § P < 0.05, Group 1 vs. other three groups
  5. + P < 0.05, Group 4 vs. other three groups